Showing results (291-300 of 302) with videos related to

Sort By:
Pageof 31
American Journal of Hematology|January 14, 2014
Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patientsRobin Foà, Ilaria Del Giudice, Antonio Cuneo, et al.
Frontiers in Oncology|August 4, 2022
Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical TrialsFortunato Morabito, Elena Zamagni, Concetta Conticello, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 2, 2016
Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung CancersKatrien Van Roosbroeck, Francesca Fanini, Tetsuro Setoyama, et al.
Haematologica|July 13, 2023
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective, real-world experience with 200 cases outside of controlled clinical trialsMassimo Gentile, Ernesto Vigna, Salvatore Palmieri, et al.
Hematological Oncology|May 31, 2024
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended follow-up of a multicenter, retrospective real-world experience with 321 cases outside of controlled clinical trialsEnrica Antonia Martino, Salvatore Palmieri, Monica Galli, et al.
European Journal of Haematology|December 30, 2020
Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia casesFortunato Morabito, Giovanni Tripepi, Giovanni Del Poeta, et al.
Blood|April 9, 2020
International prognostic score for asymptomatic early-stage chronic lymphocytic leukemiaAdalgisa Condoluci, Lodovico Terzi di Bergamo, Petra Langerbeins, et al.
Hematological Oncology|May 24, 2022
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trialsAntonella Bruzzese, Daniele Derudas, Monica Galli, et al.
Haematologica|March 6, 2025
Comparison of isatuximab-pomalidomide-dexamethasone <i>versus</i> elotuzumab-pomalidomidedexamethasone in relapsed/refractory multiple myeloma patients: a target trial emulation using real-world dataEnrica Antonia Martino, Annalisa Pitino, Massimo Offidani, et al.
European Journal of Haematology|March 19, 2025
Prognostic Significance of +1q Alterations in Relapsed/Refractory Multiple Myeloma Treated With Daratumumab-, Elotuzumab-, and Carfilzomib-Based Triplet Regimens: A Multicenter Real-World Analysis of 635 PatientsFortunato Morabito, Enrica Antonia Martino, Monica Galli, et al.
Pageof 31